RxDoctor Payments Data

Lorrie Hayes, MD

Internal Medicine · Colleyville, TXNPI 1225066913

Payments from drug & device makers

$5,700in general payments, 2019–2025

Across 366 payments — averaging $15.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$997
  • Pfizer$696
  • Novo Nordisk$558
  • Boehringer Ingelheim$383
  • Exact Sciences$371
  • Abbott$339
  • plus $2K from 37 others

What the payments were for

  • Food & beverage$5,688100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,700 in reported general payments places this provider in the 90th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$209,904
Medicare patients
395
Services billed
3,177

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide129$195,998
MounjaroTirzepatide39$73,815
TrulicityDulaglutide30$56,235
JardianceEmpagliflozin41$45,934
FarxigaDapagliflozin Propanediol36$39,901
EliquisApixaban29$37,466
XareltoRivaroxaban18$22,842
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$16,871
RybelsusSemaglutide12$14,463
SynthroidLevothyroxine Sodium133$12,877
PremarinEstrogens, Conjugated13$6,652
Rosuvastatin Calcium435$5,806
Levothyroxine Sodium493$5,590
Lantus SolostarInsulin Glargine,hum.Rec.Anlog29$5,528
Bupropion XlBupropion Hcl157$4,345

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$558$210,461141 claims
Lilly USA, LLCMounjaro, Trulicity$997$130,04969 claims
Boehringer IngelheimJardiance$383$45,93441 claims
PfizerEliquis, Premarin, Paxlovid$696$45,54757 claims
AstraZenecaFarxiga$116$39,90136 claims
Johnson & JohnsonXarelto$44$22,84218 claims
GSKTrelegy Ellipta$269$16,87120 claims
AbbVieSynthroid$286$12,877133 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Colleyville

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →